2023 Quality Assurance Reporting Requirements (QARR)
- Clarification also available in Portable Document Format (PDF)
June 5, 2023
RE: Clarification #1 for Measurement Year (MY)
2023 Updates
Dear Colleague,
This letter contains information about edits incorporated into the 2023 Quality Assurance Reporting Requirements (QARR) Technical Specifications, Patient Level Detail (PLD) for Measurement Year (MY)
2023 reporting. The information contained in this clarification has been incorporated into a revised version of the QARR Technical Specifications for MY2023. The updated files are posted on our Managed Care Information for Health Plans page. The revised specifications should be used in the plans' processing for MY2023 QARR.
This clarification includes the following changes made to the 2023 QARR Technical Specifications Manual.
Change Version | Version Date | Section(s) Changed | Change Summary |
---|---|---|---|
1 | 6.1.2023 | QARR Technical Specifications | Table 1: QARR List of Required Measures, is no longer contained within the QARR Technical Specification Manual. It is now a stand-alone document that has been posted to the NYSDOH Managed Care website under the Quality Assurance Reporting Requirements (QARR), 2023 tabs. |
Breast Cancer Screening (BCS), clarification has been added to note only the non-ECDS version has been retired by HEDIS/NCQA for MY2023. | |||
Inpatient Utilization–General Hospital/Acute Care (IPU) is not required to be reported for Essential Plans. Table 1 in the QARR Technical Specifications inadvertently had this notated as required reporting (✓). This has been corrected to an NR. | |||
Depression Remission or Response for Adolescents and Adults (DRR-E) inadvertently had the wrong short name associated with it in Table 1. This has been corrected. | |||
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E) is required for reporting on the PLD, the = was inadvertently omitted from Table 1. This has been corrected in the QARR Technical Specifications Table 1. | |||
Use of Pharmacotherapy for Alcohol Use or Dependence (POA) – The name has been updated to align with HEDIS/NCQA's Behavioral Health measures. Abuse has been updated to Use. | |||
NYS QARR Medication List and NDC codes for MY2023 have been posted to the NYSDOH Managed Care website under the Quality Assurance Reporting Requirements (QARR), 2023 tabs. | |||
Developmental Screening in the First Three Years of Life (DEV-N) numerator criteria has been updated to require both a CPT code 96110 and ICD-10-CM Code Z13.42. | |||
COVID-19 Immunization Status (CVS) specifications for this measure have not changed, but the language for the denominator criteria for rate 2 (Fully Vaccinated with Booster) has been clarified to make this clearer. Only members who are fully vaccinated are eligible to receive a booster. The denominator for rate 2 should only include members aged 5 years and older and those that were compliant with numerator 1 (fully vaccinated). | |||
Patient-Level Detail File (PLD) | Commercial PLD: Field Member ID:
|
||
Patient-Level Detail File (PLD) | Medicaid PLD: Data Source:
|
||
Patient-Level Detail File (PLD) | Exchange PLD:
Data Source:
The following ECDS measures were listed as required reporting in the QARR Technical Specifications Table 1, but omitted from the Exchange PLD, the PLD has been updated to match Table 1:
|
||
QARR Technical Specifications & Exchange Patient-Level Detail File (PLD) | ECDS Measures: To align with CMS' QRS Measure Set, the following ECDS measures have been added as required reporting on the Exchange PLD and Table 1: QARR List of Required Measures:
|
If there are any questions about the above edits, or if you find issues or have concerns with the 2023 Technical Specifications manual or the 2023 Value Set, please email nysqarr@health.ny.gov.
Sincerely,
Paloma Luisi, MPH
Director, Bureau of Quality Measurement & Evaluation
Center for Applied Research and Evaluation
Office of Quality and Patient Safety
CC: R. Josberger
B. Bandle